Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024465
Filing Date
2022-11-10
Accepted
2022-11-10 16:12:35
Documents
79
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q amlx-20220930.htm   iXBRL 10-Q 4324322
2 EX-31.1 amlx-ex31_1.htm EX-31.1 21516
3 EX-31.2 amlx-ex31_2.htm EX-31.2 21508
4 EX-31.3 amlx-ex31_3.htm EX-31.3 21508
5 EX-32.1 amlx-ex32_1.htm EX-32.1 11979
6 EX-32.2 amlx-ex32_2.htm EX-32.2 11977
7 EX-32.3 amlx-ex32_3.htm EX-32.3 12016
  Complete submission text file 0000950170-22-024465.txt   11734588

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amlx-20220930_lab.xml EX-101.LAB 471157
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT amlx-20220930_def.xml EX-101.DEF 214914
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amlx-20220930_pre.xml EX-101.PRE 366994
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amlx-20220930.xsd EX-101.SCH 53220
12 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT amlx-20220930_cal.xml EX-101.CAL 53179
73 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20220930_htm.xml XML 1955806
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 221377296
SIC: 2834 Pharmaceutical Preparations